Peramivir

This is a NOTICE OF INTENT TO AWARD A SOLE SOURCE CONTRACT. The statutory authority for this sole source procurement is prescribed in FAR 8.405-6(b). This notice is for informational and planning purposes and does not constitute a solicitation. The NAICS code for this procurement is 325412 , Pharmaceutical Preparation Manufacturing. Period of Performance is anticipated to be from date of award for approximately 60 months thereafter, including options for increased quantities. The Administration for Strategic Preparedness and Response (ASPR), Division of Strategic National Stockpile (DSNS) intends to award a sole source Firm Fixed Price contract to: BioCryst Pharmaceuticals, Inc. 4505 Emperor Blvd., Suite 200 Durham, NC 27703 In response to the ASPR/SNS mission to ensure the availability and rapid deployment of life-saving pharmaceuticals, antidotes, other medical supplies and equipment necessary to counter the effects of nerve agents, biological pathogens, and chemical agents the United States Government (USG) has a requirement for the supply of peramivir (RAPIVAB® 10mg/ml inj, soln / 200mg/20ml vial). The Contractor shall provide up to 95,625 packages of peramivir (RAPIVAB® 10mg/ml inj, soln / 200mg/20ml vial) (NDC: 72769-0181-03) per the Statement of Work. This notice of intent is NOT a request for competitive proposals. A determination to compete this procurement based on a response to this notice is solely within the discretion of the Government. All responses must be received by 19 August 2024, at 12:00 PM Eastern Standard Time. All responses must be in writing and can be sent via email to the Contracting Officer at [email protected]. Reference FY24 PERAMIVIR ACQUISITION in the subject line. No phone calls will be accepted.